ArticleJournal of bacteriology1994
A spontaneous point mutation in the single 23S rRNA gene of the thermophilic arachaeon Sulfolobus acidocaldarius confers multiple drug resistance.
Article in Journal of bacteriology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- A temperature-sensitive mutant screen reveals a translational stress-induced cell-cycle arrest in a thermophilic archaeon.Molecular biology of the cell · 2025Article
- The biology of thermoacidophilic archaea from the order Sulfolobales.FEMS microbiology reviews · 2021Article
- A versatile cis-acting element reporter system to study the function, maturation and stability of ribosomal RNA mutants in archaea.Nucleic acids research · 2020Article
- Functional characterization of the origin of replication of pRN1 from Sulfolobus islandicus REN1H1.PloS one · 2013Article
- Responses of wild-type and resistant strains of the hyperthermophilic bacterium Thermotoga maritima to chloramphenicol challenge.Applied and environmental microbiology · 2007Article
- The genome of Sulfolobus acidocaldarius, a model organism of the Crenarchaeota.Journal of bacteriology · 2005Article
- Interference probing of rRNA with snoRNPs: a novel approach for functional mapping of RNA in vivo.RNA (New York, N.Y.) · 2004Article
- A conserved chloramphenicol binding site at the entrance to the ribosomal peptide exit tunnel.Nucleic acids research · 2003Article
- Macrolide resistance conferred by base substitutions in 23S rRNA.Antimicrobial agents and chemotherapy · 2001Review
- Article
- Intercellular mobility and homing of an archaeal rDNA intron confers a selective advantage over intron- cells of Sulfolobus acidocaldarius.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- Erythromycin resistance by ribosome modification.Antimicrobial agents and chemotherapy · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of transformable vectors for thermophilic archaea requires the characterization of appropriate selectable marker genes. Many antibiotic inhibitors of protein biosynthesis are known to bind to rRNA; therefore, we screened 14 for their capacity to inhibit growth of the thermophilic archaeon Sulfolobus acidocaldarius. Carbomycin, celesticetin, chloramphenicol, puromycin, sparsomycin, tetracycline, and thiostrepton all inhibited growth by different degrees. Spontaneous drug-resistant mutants were isolated from plates containing celesticetin or chloramphenicol. Six mutants from each plate exhibited a C-2585-to-U transition in the peptidyl transferase loop of 23S rRNA (corresponding to C-2452 in Escherichia coli 23S rRNA). The single-site mutation also conferred resistance to carbomycin. The mutated 23S rRNA gene provides a potentially useful and dominant marker for a thermophilic archael vector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.